Polysensitisation is associated with more severe symptoms: The reality of patients with allergy
Clinical & Experimental Allergy · 2024-08 · 54 (8) · 607-620
DOI: 10.1111/cea.14486 ↗At a glance
Multizentrische Studie in Clinical & Experimental Allergy, published online on 2024-04-27. Written by Cristina Cacheiro-Llaguno and 5 co-authors. Institution: R&D Allergy and Immunology Unit, LETI Pharma, Madrid, Spain. Major MEDLINE topics: Immunoglobulin E, Allergens, Hypersensitivity. Cited 26 times so far (Crossref); 99 references.
Abstract (original language)
Background
Studying the sensitisation profiles of patients with allergies allows for a deeper understanding of the disease which may facilitate the selection of the best‐personalised allergen immunotherapy. This observational, cross‐sectional, multicentre study aimed to demonstrate the heterogeneity of the German population with allergies by analysing specific immunoglobulin E (sIgE) patterns towards aeroallergens and exploring the relationship between sensitisation and clinical symptoms.
Methods
In total, 500 patients with allergies from different regions of Germany were recruited based on their case histories, clinical allergic symptoms and skin prick test data for aeroallergens. Serum samples were analysed using ImmunoCAP assays to determine sIgE levels for 33 allergenic sources and 43 molecular allergens.
Results
Most patients (81%) were polysensitised. Betula verrucosa pollen was the most common cause of sensitisation (59%), followed by Phleum pratense (58%) and Dermatophagoides pteronyssinus (44%). The highest prevalence rates of molecular allergens were observed for Bet v 1 (84%) from birch pollen, Phl p 1 from grass pollen (82%), Der p 2 (69%) from mites and Fel d 1 (69%) from cat. Polysensitisation was significantly associated with the presence of asthma and the severity of rhinitis symptoms.
Conclusions
Our findings show a high rate of polysensitisation and emphasise the importance of molecular diagnosis for more precise and comprehensive insights into sensitisation patterns and their association with clinical symptoms. These data may help improve personalised diagnosis and immunotherapy adapted to the needs of individual patients in the region.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- R&D Allergy and Immunology Unit, LETI Pharma, Madrid, Spain.
- IMSB, Faculty of Medicine, University of Cologne, Cologne, Germany.
- ClinCompetence Cologne GmbH, Cologne, Germany.
- Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Genomic and NGS Facility (GENGS), Madrid, Spain.
- Praxis Dr. Kasche und Kollegen, Hamburg, Germany.
ORCID profiles: Cristina Cacheiro-Llaguno, Ralph Mösges, David Calzada, Sandra González-de la Fuente, Eliana Quintero, Jerónimo Carnés
Cite
APA
Cacheiro-Llaguno, C., Mösges, R., Calzada, D., González-de la Fuente, S., Quintero, E., & Carnés, J. (2024). Polysensitisation is associated with more severe symptoms: The reality of patients with allergy. Clinical & Experimental Allergy, 54(8), 607-620. https://doi.org/10.1111/cea.14486
Vancouver
Cacheiro-Llaguno C, Mösges R, Calzada D, González-de la Fuente S, Quintero E, Carnés J. Polysensitisation is associated with more severe symptoms: The reality of patients with allergy. Clinical & Experimental Allergy. 2024;54(8):607-620. doi:10.1111/cea.14486
BibTeX
@article{CacheiroLlaguno2024,
author = {Cacheiro-Llaguno, Cristina and Mösges, Ralph and Calzada, David and González-de la Fuente, Sandra and Quintero, Eliana and Carnés, Jerónimo},
title = {Polysensitisation is associated with more severe symptoms: The reality of patients with allergy},
journal = {Clinical & Experimental Allergy},
year = {2024},
volume = {54},
number = {8},
pages = {607--620},
doi = {10.1111/cea.14486}
}
EUVIMED